SCHEDULE: Samsara BioCapital Divests Entire Stake in Cargo Therapeutics

Samsara BioCapital, L.P., along with its general partner and managing member, Srinivas Akkaraju, reported a complete divestment of their beneficial ownership in Cargo Therapeutics, Inc. common stock.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The Reporting Persons now beneficially own 0.0% of the Common Stock, par value $0.001, of CARGO THERAPEUTICS, INC.
• This filing indicates a complete divestment of their previous holdings in the company.
• The event requiring this filing, which is the change in beneficial ownership, occurred on September 30, 2025.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The complete divestment by an institutional investor is a negative signal, indicating a lack of continued confidence or a strategic exit. This could put downward pressure on the stock.

Negatives

• A significant institutional investor, Samsara BioCapital, has completely divested its holdings in Cargo Therapeutics, Inc., which could be interpreted as a lack of confidence in the company's future prospects by this investor.

Risks

• The complete divestment by an institutional investor like Samsara BioCapital could signal potential underlying concerns about Cargo Therapeutics, Inc.'s performance, pipeline, or market position, which may not be immediately apparent to other investors.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Cargo Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.

Industry Context

The divestment by a venture capital firm specializing in biotechnology, like Samsara BioCapital, can sometimes reflect a strategic shift in their portfolio, a realization of gains, or a re-evaluation of the investment thesis for a particular company within the competitive biotech landscape. While not explicitly stated, such a move by an early-stage investor could be watched by the market for signals regarding the company's long-term potential or specific project milestones.

Stakeholder Impact

• Shareholders: May view the divestment by an institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company Management: Could face questions regarding the reasons for the institutional investor's exit and may need to address market concerns.

Key Dates

Recommendation

The complete divestment by a specialized biotech investor like Samsara BioCapital, particularly as an amendment to a 13G indicating a prior significant stake, is a strong negative signal. It suggests that this informed investor no longer sees value or potential in Cargo Therapeutics, Inc. This could lead to a decline in share price as other investors react to the news, making a 'sell' recommendation prudent for existing holders to mitigate potential losses, or a 'hold' for those who believe the market reaction might be overblown but with significant risk.

Keywords

Cargo Therapeutics, Samsara BioCapital, Srinivas Akkaraju, Divestment, Institutional Ownership, Biotechnology, SEC Filing, Schedule 13G, Common Stock